JBIO Jade Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: JBIO

Price (delayed)

$14.71

Market cap

$935.52M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.92

Enterprise value

$828.9M

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 55
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

Aerovate Therapeutics is a biotechnology company that was focused on improving the lives of patients with rare cardiopulmonary disease.

Highlights
The company's equity has surged by 118% YoY and by 48% QoQ
JBIO's EPS has soared by 92% year-on-year and by 5% since the previous quarter
The net income has dropped by 65% year-on-year and by 18% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of JBIO

JBIO stock price

How has the Jade Biosciences stock price performed over time
Intraday
-12.23%
1 week
-11.65%
1 month
-31.07%
1 year
93.3%
YTD
-4.67%
QTD
-33.8%

Financial performance

How have Jade Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$164.74M
Net income
-$153.24M
Gross margin
N/A
Net margin
N/A
JBIO's operating income has dropped by 125% year-on-year and by 23% since the previous quarter
The net income has dropped by 65% year-on-year and by 18% since the previous quarter

Price vs fundamentals

How does JBIO's price correlate with its fundamentals

Growth

What is Jade Biosciences's growth rate over time

Valuation

What is Jade Biosciences stock price valuation
P/E
N/A
P/B
1.65
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
JBIO's EPS has soared by 92% year-on-year and by 5% since the previous quarter
The company's equity has surged by 118% YoY and by 48% QoQ
The price to book (P/B) is 35% less than the 5-year quarterly average of 2.9 and 10% less than the last 4 quarters average of 2.1

Efficiency

How efficient is Jade Biosciences business performance
The company's return on invested capital has surged by 72% YoY and by 25% QoQ
The return on equity has surged by 59% year-on-year and by 4.3% since the previous quarter
The return on assets is up by 43% year-on-year and by 3.6% since the previous quarter

Dividends

What is JBIO's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Jade Biosciences financials performed over time
JBIO's total assets has surged by 111% year-on-year and by 48% since the previous quarter
Jade Biosciences's current ratio has increased by 45% YoY and by 4.5% from the previous quarter
JBIO's debt is 100% less than its equity
The company's equity has surged by 118% YoY and by 48% QoQ
JBIO's debt is down by 21% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.